指南与共识心脑血管急症重症综合管理与镇静镇痛

微创脑出血清除术后治疗性低温的共识推荐:脑出血低温(HICH)工作组

Consensus recommendations on therapeutic hypothermia after minimally invasive intracerebral hemorrhage evacuation from the hypothermia for intracerebral hemorrhage (HICH) working group.
指南 / 共识 · Front Neurol · 2022-08-17
一句话结论HICH工作组共识推荐:微创脑出血清除术后,全身常温联合局部中度(33.5°C)低温是最有前景的治疗策略,需进一步研究验证。

该共识由国际专家小组制定,旨在为微创脑出血清除术后联合治疗性低温(TH)/目标温度管理(TTM)的临床试验设计和结局提供推荐。工作组于2020年12月至2021年2月通过三次专题会议和三次全体会议,分析现有证据并就冷却方案关键要素和试验设计达成共识。推荐详细描述了临床冷却方案的关键要素、验证TH联合血肿清除的试验实施框架以及改进冷却方法的后期方案。共识认为全身常温联合局部中度(33.5°C)低温是最有前景的治疗策略,但更多研究仍需开展以进一步优化该患者群体的应用。

要点

  • 共识推荐将全身常温与局部中度(33.5°C)低温联合使用,视为微创脑出血清除术后最有前景的治疗策略。
  • 推荐内容涵盖临床冷却方案的关键要素,以及验证治疗性低温联合血肿清除的临床试验实施框架。
  • 工作组由危重症治疗性低温与脑出血交叉领域的国际专家组成,通过三次专题会议和三次全体会议形成共识。
  • 治疗性低温在脑出血患者中尚未证实临床获益,微创清除术在大型随机试验中亦未证实功能改善。
  • 共识指出需更多研究进一步优化治疗性低温在微创脑出血清除术后患者中的应用与联合方式。

适用人群与场景

  • 接受微创清除术的脑出血(ICH)患者,为治疗性低温(TH)/目标温度管理(TTM)联合应用的候选人群。

处置流程与药物剂量

  • 共识推荐的最有前景治疗策略为全身常温联合局部中度(33.5°C)低温。
  • 推荐详细描述了临床冷却方案的关键要素,以及验证治疗性低温联合血肿清除的临床试验实施框架和改善冷却方法的后期方案。

研究设计与关键结果

  • 工作组于2020年12月至2021年2月通过三次专题会议和三次全体会议,分析现有证据并就冷却方案关键要素和临床试验设计达成共识。
  • 共识推荐将全身常温联合局部中度(33.5°C)低温确定为最有前景的治疗策略。
  • 推荐内容涵盖临床冷却方案关键要素、验证治疗性低温联合血肿清除的临床试验实施框架以及改善冷却方法的后期方案。

证据类型、等级与局限

  • 证据类型:国际专家工作组共识推荐。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,微创脑出血清除术后可考虑采用全身常温联合局部中度(33.5°C)低温的策略,但需在临床试验框架下进一步验证。
  • 共识指出治疗性低温在脑出血患者中尚未证实临床获益,微创清除术在大型随机试验中亦未证实功能改善,临床决策需结合研究背景。
  • 共识强调需更多研究进一步优化治疗性低温在微创脑出血清除术后患者中的应用与联合方式。

指南或共识出处

  • 脑出血低温(HICH)工作组共识推荐,发表于 Frontiers in Neurology。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Therapeutic hypothermia (TH), or targeted temperature management (TTM), is a classic treatment option for reducing inflammation and potentially other destructive processes across a wide range of pathologies, and has been successfully used in numerous disease states. The ability for TH to improve neurological outcomes seems promising for inflammatory injuries but has yet to demonstrate clinical benefit in the intracerebral hemorrhage (ICH) patient population. Minimally invasive ICH evacuation also presents a promising option for ICH treatment with strong preclinical data but has yet to demonstrate functional improvement in large randomized trials. The biochemical mechanisms of action of ICH evacuation and TH appear to be synergistic, and thus combining hematoma evacuation with cooling therapy could provide synergistic benefits. The purpose of this working group was to develop consensus recommendations on optimal clinical trial design and outcomes for the use of therapeutic hypothermia in ICH in conjunction with minimally invasive ICH evacuation.

METHODS: An international panel of experts on the intersection of critical-care TH and ICH was convened to analyze available evidence and form a consensus on critical elements of a focal cooling protocol and clinical trial design. Three focused sessions and three full-group meetings were held virtually from December 2020 to February 2021. Each meeting focused on a specific subtopic, allowing for guided, open discussion.

RESULTS: These recommendations detail key elements of a clinical cooling protocol and an outline for the roll-out of clinical trials to test and validate the use of TH in conjunction with hematoma evacuation as well as late-stage protocols to improve the cooling approach. The combined use of systemic normothermia and localized moderate (33.5°C) hypothermia was identified as the most promising treatment strategy.

CONCLUSIONS: These recommendations provide a general outline for the use of TH after minimally invasive ICH evacuation. More research is needed to further refine the use and combination of these promising treatment paradigms for this patient population.

来源:Front Neurol,查看原文。版权归原作者所有。

参考来源

  1. Baker TS, Kellner CP, Colbourne F, et al. Consensus recommendations on therapeutic hypothermia after minimally invasive intracerebral hemorrhage evacuation from the hypothermia for intracerebral hemorrhage (HICH) working group. Front Neurol. 2022. PMID: 36062017. doi:10.3389/fneur.2022.859894

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。